Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate

Urology

Volumn 61, Issue 4, 2003, Pages 730-735

  Roach III, Mack ^a   Weinberg, Vivian ^b   McLaughlin, Patrick W ^b   Grossfeld, Gary ^b   Sandler, Howard M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD LEVEL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RISK ASSESSMENT;

EID: 0037382661     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02425-1     Document Type: Article

References (20)

1. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. JAMA. 277:1997;1452-1455.
2. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 277:1997;1445-1451.
3. Zagars G.K., Pollack A., von Eschenbach A.C. Prognostic factors for clinically localized prostate cancer analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 79:1997;1370-1380.
4. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 5:1999;152-158.
5. Roach M. The role of PSA in the radiotherapy of prostate cancer. Oncology. 10:1996;1143-1153.
6. Roach M., Lu J., Pilepich M.V., et al. Four prognostic groups predict long term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 47:2000;609-615.
7. Roach M., Lu J., Pilepich M.V., et al. Predicting long term survival and the need for hormonal therapy a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 47:2000;617-627.
8. Consensus statement guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
9. Sandler H.M., Perez-Tamayo C., Ten Haken R.K., et al. Dose escalation for stage C (T3) prostate cancer minimal rectal toxicity observed using conformal therapy. Radiother Oncol. 23:1992;53-54.
10. Pickett B., Roach M., Horine P., et al. Optimization of the oblique angles in the treatment of prostate cancer during six-field conformal radiotherapy. Med Dosim. 19:1994;237-254.
11. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
12. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer a multi-institutional pooled analysis. JAMA. 281:1999;1598-1604.
13. Peto R.P.J. Asymptotically efficient rank invariant procedures. Roy Stat Soc Series A. 135:1972;185-207.
14. Cox D.R. Regression models and life tables. J Roy Stat Soc. 34:1972;187-202.
15. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer. 79:1997;337-344.
16. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 18:2000;3352-3359.
17. Zelefsky M.J., Leibel S.A., Wallner K.E., et al. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J Clin Oncol. 13:1995;459-463.
18. Hanks G.E., Hanlon A.L., Hudes G., et al. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy the need for improved systemic and locoregional treatment. J Clin Oncol. 14:1996;1093-1097.
19. Iselin C.E., Robertson J.E., Paulson D.F. Radical prostatectomy oncological outcome during a 20 year period. J Urol. 161:1999;163-168.
20. Taylor J.M.G., Griffith K.A., Sandler H.M. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys. 50:2001;1212-1219.